🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are increasing worldwide, with estimates suggesting in excess of 82 million infections per year. Notably increased rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, the spread of superbugs and the highly restricted available drugs currently available.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The global health body has designated it as a "critical concern". A tracking program found that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, also known as a brand name, was approved by the US FDA in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Scientists hope that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in close succession. This medication, which is additionally indicated for UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This approval marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to findings detailed in a major medical journal, the new drug cured the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which involves two antibiotics. The study involved over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the ability to register and commercialise the drug in many developing nations.

Doctors on the front lines have expressed optimism. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for gonorrhoea control. This is deemed vital to reduce the burden of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.